Lexaria launches 2026 research program for drug delivery tech

Entity Intersection Graph

No entity connections available yet for this article.

}

Original Source

              KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX) announced today the start of its 2026 research and development program focused on drug delivery platform development through new formulations. The company, with a market capitalization of $16.8 million, is trading at $0.68 per share, down 44% over the past year.
            

Read full article at source